NCI-H1155細胞

生長狀態： 懸浮生長，簇狀懸浮

數量： 大量

年限： 36 years

運輸方式： 凍存運輸

細胞形態： 上皮樣

ATCC Number： CRL-5818?

相關**： 非小細胞肺癌

是否是腫瘤細胞： 1

物種來源： 人

器官來源： 肺

NCI-H1155細胞Designations: NCI-H1155 [H1155]

Depositors: AF Gazdar, JD Minna

Biosafety Level: 1

Shipped: frozen

Medium & Serum: See Propagation

Growth Properties: clusters in suspension

Organism: Homo sapiens

Morphology: epithelial

Source: Organ: lung

Disease: carcinoma; non-small cell lung cancer

Derived from metastatic site: lymph node

Cellular Products: neuromedin B (NMB)

Permits/Forms: NCI-H1155細胞In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.

Restrictions: The line is available with the following restrictions: 1. This cell line was deposited at the ATCC by Dr. A. Gazdar and Dr. J. Minna and is provided for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purposes of sale, or producing for sale, cells or their products. The cells are provided as service to the research community. They are provided without warranty of merchantability or fitness for a particular purpose or any other warranty, expressed or implied. 2. Any proposed commercial use of the these cells, or their products must first be negotiated with the University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, Texas 75235. Telephone (214) 699-8056, FAX (214) 688-7233.

DNA Profile (STR): Amelogenin: X

CSF1PO: 12

D13S317: 14

D16S539: 9

D5S818: 10

D7S820: 8

THO1: 6

TPOX: 8

NCI-H1155細胞vWA: 15

Age: 36 years

Gender: male

Ethnicity: Caucasian

Comments: This line was derived by A.F. Gazdar, H.K. Oie, J.D. Minna and associates from a lymph node metastasis obtained from a patient prior to therapy.

The cells are able to synthesize the peptide NMB at 0.2 pmol/mg protein, but not the gastrin releasing peptide (GRP).

Propagation: ATCC complete growth medium: ACL-4 medium (serum-free)

The base medium for this cell line is ATCC formulated DMEM: F12 Medium Catalog No. 30-2006. To make the complete growth medium, add the following components to the base medium:

0.02 mg/ml insulin

0.01 mg/ml transferrin

25 nM sodium selenite (final conc.)

50 nM Hydrocortisone (final conc.)

1 ng/ml Epidermal Growth Factor (do not filter)

0.01 mM ethanolamine (final conc.)

0.01 mM phosphorylethanolamine (final conc.)

100 pM triiodothyronine (final conc.)

0.5% (w/v) bovine serum albumin (final conc.)

0.5 mM sodium pyruvate NCI-H1155細胞(final conc.)

extra 2mM L-glutamine (for final conc. of 4.5mM)

Temperature: 37.0°C

Subculturing: Medium Renewal: Every 2 to 3 days

Cultures can be maintained by addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation of the suspension with subsequent resuspension in fresh medium. Add medium as the cell density increases.

Preservation: Culture medium, 95%; DMSO, 5%

Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2006

References: 23517: Giaccone G, et al. Neuromedin B is present in lung cancer cell lines. Cancer Res. 52: 2732s-2736s, 1992. PubMed: 1563005

23570: . NCI-Navy Medical Oncology Branch Cell Line Supplement. J. Cell. Biochem. suppl. 24: 1996.